Previous close | 53.97 |
Open | 54.43 |
Bid | 53.19 x 800 |
Ask | 54.31 x 900 |
Day's range | 54.16 - 54.52 |
52-week range | 36.91 - 58.10 |
Volume | |
Avg. volume | 2,014,909 |
Market cap | 135.91B |
Beta (5Y monthly) | 0.39 |
PE ratio (TTM) | 15.20 |
EPS (TTM) | 3.58 |
Earnings date | N/A |
Forward dividend & yield | 1.90 (3.50%) |
Ex-dividend date | 25 May 2023 |
1y target est | 63.50 |
On March 23, Sanofi (NASDAQ: SNY) and Regeneron's (NASDAQ: REGN) Dupixent shared positive results in its phase 3 clinical trial of patients with uncontrolled, chronic obstructive pulmonary disease (COPD). Let's take a look at the clinical data and the global COPD market to assess the sales potential of the drug.
Availability of the Q1 2023 Memorandum for modelling purposes Paris, France – March 30, 2023 - Sanofi announced today that its Q1 2023 Memorandum for modelling purposes is available on the "Investors" page of the company's website: https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/Q1-results-2023 As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various no
Sanofi (SNY) closed at $53.22 in the latest trading session, marking a +1.16% move from the prior day.